Lv5
1090 积分 2024-05-13 加入
The global burden of inflammatory bowel disease: from 2025 to 2045
1天前
待确认
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
27天前
已完结
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
27天前
已完结
Theoretical analysis of efficacy of biological agent for rheumatoid arthritis based on target molecular binding occupancy
2个月前
已完结
Evidence-Based Psoriasis
4个月前
已完结
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials
5个月前
已完结
皖公网安备34019202002308
